Company / Cash & Equivalents
Cocrystal Pharma, Inc. Cash & Equivalents History
FY2012-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$58.7M
FY2021
5-year range
$4.7M / $58.7M
FY2017-FY2021
Trend
+77.8%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $5M to $59M over the past 9 years.
Based on SEC 10-K filings.
$59M in FY2021.
Improved from $5M to $59M over the past 9 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, cash & equivalents increased 77.8% year-over-year.
Company context
Key Data Points
- Altman Z-Score 14.87 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $58.7M | +77.8% |
| FY2020 | $33.0M | - |
| FY2019 | - | - |
| FY2012 | $4.7M | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026